| HOME >> BIOLOGY >> TECHNOLOGY |
Advances to suppliers (662,079) (761,889)
Other current assets (79,904) (44,544)
Change in operating liabilities
Accounts payable, trade (30,774) 46,475
Other payables and accrued liabilities (49,957) (5,688)
Customer deposits (54,499) 54,531
Taxes payable (142,540) 36,802
Net cash used in operating
activities (1,142,167) (871,460)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment (4,490) (35,399)
Purchase of intangible asset - (129,010)
Net cash used in investing
activities (4,490) (164,409)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants
and options 362,500 2,838,062
Net cash provided by financing
activities 362,500 2,838,062
EFFECT OF EXCHANGE RATE ON CASH 193,444 138,282
INCREASE (DECREASE) IN CASH (590,713) 1,940,475
CASH, beginning of period 5,767,774 371,480
CASH, end of period $5,177,061 $2,311,955
Company Contact: Investor Relations Contact:
Ms. Huizhen Yu Mr. Crocker Coulson
Chief Financial Officer President
China Medicine Corp CCG Elite Investor Relations
Tel: +86-20-8739-1718 Tel: +1-646-213-1915 (NY Office)
E-mail: konzern08@163.com
'/>"/>
| SOURCE China Medicine Corporation Copyright©2008 PR Newswire. All rights reserved |